- Home
- GRX vs CGEN Comparison
GRX vs CGEN Comparison
Compare GRX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- CGEN
- Stock Information
- Founded
- GRX 2007
- CGEN 1993
- Country
- GRX United States
- CGEN Israel
- Employees
- GRX N/A
- CGEN N/A
- Industry
- GRX Finance/Investors Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRX Finance
- CGEN Health Care
- Exchange
- GRX Nasdaq
- CGEN Nasdaq
- Market Cap
- GRX 149.2M
- CGEN 135.6M
- IPO Year
- GRX N/A
- CGEN 2000
- Fundamental
- Price
- GRX N/A
- CGEN $1.47
- Analyst Decision
- GRX
- CGEN Strong Buy
- Analyst Count
- GRX 0
- CGEN 1
- Target Price
- GRX N/A
- CGEN $4.00
- AVG Volume (30 Days)
- GRX 39.7K
- CGEN 268.4K
- Earning Date
- GRX 01-01-0001
- CGEN 05-19-2025
- Dividend Yield
- GRX 5.98%
- CGEN N/A
- EPS Growth
- GRX N/A
- CGEN N/A
- EPS
- GRX 0.26
- CGEN N/A
- Revenue
- GRX N/A
- CGEN $27,864,000.00
- Revenue This Year
- GRX N/A
- CGEN $11.81
- Revenue Next Year
- GRX N/A
- CGEN $28.37
- P/E Ratio
- GRX $38.50
- CGEN N/A
- Revenue Growth
- GRX N/A
- CGEN N/A
- 52 Week Low
- GRX $7.73
- CGEN $1.13
- 52 Week High
- GRX $10.40
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- GRX 39.96
- CGEN 49.50
- Support Level
- GRX $9.36
- CGEN $1.13
- Resistance Level
- GRX $9.59
- CGEN $1.35
- Average True Range (ATR)
- GRX 0.29
- CGEN 0.11
- MACD
- GRX -0.02
- CGEN 0.03
- Stochastic Oscillator
- GRX 35.24
- CGEN 85.00
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.